MMJ Recs

MAY 15, 2024

Anxiety is a mental health disorder that stands as one of the most prevalent and debilitating conditions affecting millions of individuals worldwide. Anxiety disorders encompass a range of conditions characterized by excessive worry, fear, and apprehension. It leads to avoidance behaviors and profound distress in social settings.

Marijuana 105

Marijuana Therapy Treatment Sleep 105

Illinois News Joint

APRIL 10, 2023

Senior Care & Cannabis: An Introduction is a free digital workshop for older adults, their children, and healthcare providers who are curious about adding a cannabis-based therapy to their healthcare routine. Upcoming events include information on Anxiety, Autism, PSTD, and Women’s Health. Thursday, April 13.

Therapy 98

Therapy Events Advocacy Cannabis 98

MMJ Recs

JULY 11, 2024

It is often caused by life events such as stress, anxiety, or a significant change in routine. It can be caused by a variety of factors, including medical conditions, psychological issues, or environmental factors. It can be caused by underlying health conditions, medications, or psychological factors.

Sleep 111

Sleep Treatment Research and Development Therapy 111

NORML

FEBRUARY 1, 2019

And officials in San Francisco, California are considering a proposal to allow marijuana to be socially consumed and sold at temporary events. Senate Bill 19-013 would permit physicians to recommend cannabis therapy for any condition for which an opiate would otherwise be prescribed. CA resident? CO resident? Connecticut.

Legislation 178

Legislation Decriminalization Access Patients 178

Cannabis Law Report

JANUARY 26, 2022

MDMA as an adjunct to therapy for PTSD is the forty-first treatment to receive the Innovation Passport since its inception in January 2021. The designation is intended to accelerate the timeline for approval of innovative medicines for treatment of life-threatening conditions or those which present a significant patient or public health need.

Therapy 52

Therapy Clinical Trials Research and Development Treatment 52

SpeedWeed

MARCH 26, 2021

That’s just one step being taken to prepare the state for the eventual implementation of Measure 109, in which 56 percent of voters approved last fall to legalize psychedelic mushroom therapy. . The post This New BIPOC-Run Group Is Educating People About Legal Mushroom Therapy in Oregon appeared first on SpeedWeed.

Therapy 52

Therapy Education Legalization Media 52

NORML

MARCH 1, 2019

Senate Bill 19-013 would permit physicians to recommend cannabis therapy for any condition for which an opiate would otherwise be prescribed. House Bill 19-1028 would permit physicians to recommend cannabis therapy to those diagnosed with an autism spectrum disorder. MD resident? MN resident? North Dakota.

Legislation 185

Legislation Compliance Compliance Hemp 185

Veriheal

AUGUST 21, 2023

The non-profit seeks to explore how psychedelics, such as MDMA , LSD, and psilocybin (the active ingredient in magic mushrooms), can be utilized in a controlled and supervised environment to treat various medical conditions like depression, anxiety, PTSD, and addiction.

Therapy 95

Therapy Research and Development Treatment Environment 95

Medical Marijuana Pages

JANUARY 12, 2025

Post-traumatic stress disorder (PTSD) is a debilitating condition that affects millions worldwide, often resulting from exposure to traumatic events. Despite advancements in therapy and medication, many individuals. Medical Cannabis and its Promising Effects in Treating PTSD. Read More

Therapy 62

Therapy Events Conditions Cannabis 62

The Cannigma

JULY 17, 2022

You don’t need a medical condition or a paid subscription – the ROC serves curious consumers, medical professionals, and anyone else who is looking to better their life through cannabinoid therapies. To support their efforts in providing free cannabis education, the ROC hosts fundraisers and advocacy events to raise money.

Advocacy 135

Advocacy Education Events Epilepsy 135

Cannabis Law Report

JUNE 28, 2021

Pharmaceutical and Medical Cannabis Leaders Zambon GmbH and Adven GmbH will Drive Medical Cannabis Supporting Treatments for Neurological Therapies. The aim of the agreement is to make medical cannabis treatments available to patients, with an initial focus on neurological therapies. It is expected to be worth USD 2.1

Access 105

Access Research and Development Pharmaceutical Therapy 105

Illinois News Joint

MAY 3, 2023

This workshop caters to adult women and/or healthcare providers who are curious about adding a cannabis-based therapy to their healthcare routine, including menstrual cycle support, menopausal symptom relief, sexual wellness, gynecological conditions (endometriosis, PCOS), and autoimmune disorders (high prevalence in women).

Advocacy 98

Advocacy Therapy Events Conditions 98

The Joint Blog

APRIL 17, 2020

But as an older user-base with more complicated medical conditions continue to grow, it is important to understand how THC could adversely impact other co-administered medications. Medical cannabis is typically prescribed for patients with severe conditions including inflammatory conditions (e.g.,

Events 48

Events THC Chronic Pain Conditions 48

Veriheal

JUNE 29, 2022

COMPASS used their own psilocybin, called COMP360, to lead the largest randomized, controlled, double-blind study into psilocybin therapy, the results of which were shared at the American Psychiatric Association’s (APA) annual meeting in New Orleans. The patients were supervised for 12 weeks after having been administered their dosages.

Clinical Trials 105

Clinical Trials Blood Pressure Treatment Therapy 105

Medicinal Genomics

APRIL 9, 2025

Infestations and infections can spread rapidly in controlled environments, especially if inconsistent cultivation protocols are in place, creating ideal conditions for them to invade your grow. Pythium species can survive in soil for long periods as sexual spores called oospores, which can infect plant roots in damp conditions.

Environment 69

Environment Cultivation Research and Development Terpenes 69

CannaMD

MAY 25, 2021

These findings could point to new cannabis-based therapies for both the healing of broken bones and the slowing of degenerative osteoporosis. These findings might indicate that cannabis therapies with a higher CBD content would prove more beneficial for bone healing and regrowth. THC, CBD & THE ECS. MARIJUANA AND OSTEOPOROSIS.

Marijuana 111

Marijuana Research and Development Clinical Trials THC 111

Cannabis Law Report

AUGUST 25, 2021

Lucid has successfully developed a strong pipeline of novel therapeutic compounds — supported by IP in order to advance to future clinical trials — and we are confident that the experience the Lucid leadership team brings will allow us to immediately start the process towards clinical trials to further advance these promising therapies.

Clinical Trials 85

Clinical Trials Research and Development Therapy Conditions 85

Cannabis Law Report

NOVEMBER 26, 2019

In Canada today, close to 70% of all those surveyed aged 19+ believe that cannabis is an alternate form of treatment to some medical conditions according to Vividata’s Vivintel , the nation’s largest syndicated cannabis consumer study. We are partnering with Canopy Growth to offer a unique event of fun and canna-learning.

Chronic Pain 91

Chronic Pain Events Education THC 91

United Patients Group

DECEMBER 5, 2023

One area of focus is its potential for treating mental health conditions. Anxiety Disorders and Medical Cannabis Anxiety disorders are among the most common mental health conditions in the United States, affecting millions of adults each year. In this day and age, the use of medical cannabis is no longer a fringe idea.

Research and Development 105

Research and Development Treatment Patients Conditions 105

Cannabis Law Report

JUNE 23, 2021

. “We are excited to be initiating our pilot program with Medicann in Jersey, which represents a unique, ‘ring-fenced’ environment for establishing potentially numerous studies on the efficacy of treatments using plant-based therapies.

Programs 100

Programs Data Events Collective 100

Cannabis Law Report

JULY 12, 2019

Rachel Levine today announced that effective July 20, anxiety disorders and Tourette syndrome will be approved serious medical conditions in the medical marijuana program based on the recommendation of the Medical Marijuana Advisory Board and a review of medical research on the use of marijuana to treat these conditions.

Conditions 40

Conditions Programs Research and Development Marijuana 40

Cannabis Law Report

SEPTEMBER 9, 2021

Investors may register for the conference at the event website. The live and archived webcast will be available for 90 days after the event. MYMD-1 is also being developed as a potential therapy for COVID-19-related conditions such as post-COVID-19 syndromes. During this presentation, Chris Chapman, M.D., 646) 421-9523.

Pharmaceutical 74

Pharmaceutical Clinical Trials Chronic Pain Epilepsy 74

TheAnswerPage

JANUARY 11, 2022

For example, most, if not all, states have legalized the use of medical marijuana to treat specific health conditions for which there is no or only poor quality clinical evidence of efficacy and safety. Who monitors their health and the long-term effects of the marijuana therapy?

Patients 98

Patients Education Marijuana Therapy 98

Cannabis Law Report

AUGUST 9, 2021

Through the agreement, BevCanna will also be able to leverage Keef’s extensive US manufacturing and distribution network to launch their own line of products into the US, in the event of positive federal regulatory reform. About BevCanna Enterprises Inc. BevCanna Enterprises Inc. cannabis beverage company Keef Brands.

Events 81

Events Retail Therapy Cannabis 81

Cannabis Law Report

JULY 27, 2021

The longitudinal study showed that individuals who used artisanal cannabidiol (CBD) products reported better quality of life, lower psychiatric symptom severity and fewer medication-related adverse events compared with those not using CBD. This study represents a refreshing collaboration of scientists, clinicians, patients and advocates.

Data 81

Data Epilepsy Research and Development Clinical Trials 81

Cannabis Law Report

JUNE 16, 2021

With increased capacity to screen patients, on a genetic basis, for underlying psychiatric disorders prior to undertaking PAP, Entheon is furthering its commitment toward safety and predictability in psychedelic therapies while aggregating data that can be used to determine which psychedelic molecules are best-suited for a particular patient.”

Research and Development 105

Research and Development Data Conditions Events 105

LifeCannMD

MAY 27, 2025

Now, with 1.5mg of a balanced THC:CBD tincture twice daily, he’s giving presentations at work and actually enjoying social events again. He’s now able to attend his daughter’s school events without panic attacks. Traditional medications left him feeling like a zombie. “What About Tolerance?”

Microdosing 52

Microdosing Research and Development Sleep Chronic Pain 52

MMJ Recs

DECEMBER 15, 2023

The use of medical marijuana to treat insomnia has gained attention as a potential alternative or complementary therapy. Today we’ll be taking a closer look at what the condition of insomnia involves, how it might be treated with the use of medical marijuana, and what the best MMJ strains for insomnia are. What is Insomnia?

Strains 98

Strains Sleep THC Chronic Pain 98

The Cannigma

OCTOBER 21, 2021

Attention deficit hyperactivity disorder, or ADHD, is a condition characterized by behavioral symptoms such as inattentiveness, hyperactivity, impulsiveness. While there has been little systematic research on using cannabis for ADHD, many patients with the condition report positive effects from using cannabis. What is ADHD?

Blood Pressure 137

Blood Pressure Treatment Patients Cannabis 137

Veriheal

FEBRUARY 28, 2021

It helps to showcase the 103 countries holding events on this day as well as the thousands of events hosted online worldwide. This year, COVID-19 has dramatically impacted the way events are hosted. Instead of having physical locations, many events have opted to go digital being held online.

Chronic Pain 52

Chronic Pain Events Therapy Treatment 52

Cannabis Law Report

JANUARY 12, 2022

The sale will accelerate the development of Gb Sciences’ proprietary Parkinson’s disease and COVID-related Cytokine-Release Syndrome therapies. “This is a landmark event for Gb Sciences,” said Chairman and CEO John Poss. LAS VEGAS, Jan. 11, 2022 (GLOBE NEWSWIRE) — Gb Sciences, Inc. 31, 2021.

Research and Development 52

Research and Development Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

AUGUST 23, 2021

FDA has not reviewed the manufacturing process of these unapproved CBD-containing drug products, so the manufacturing conditions of, or contaminant levels in, these products is unknown. Practicing veterinarians face a barrage of questions from pet owners about the use of CBD animal products for conditions ranging from arthritis to anxiety.

Pets 105

Pets Hemp CBD Food 105

The Cannigma

OCTOBER 9, 2021

The common understanding is that every individual has a separate and different reaction to cannabinoid-based therapy, the same is true with how it might influence individual urinary symptoms. The effects of cannabis on micturition are complex with many factors at play.

Consumption 98

Consumption Cannabinoids Patients Cannabis 98

Cannabis Law Report

DECEMBER 1, 2021

Join Chacruna and mental health experts and activists, Allison Feduccia, PhD, Vilmarie Fraguada Narloch, PsyD, Kylea Taylor, MS, LMFT, and Emma Knighton, MA, LMHC, to discuss topics around standards of care and accountability for practitioners in the psychedelic-therapy space, addressing issues of power, hierarchy, and abuse.

Safety 52

Safety Medicine Therapy Research and Development 52

Cannabis Law Report

AUGUST 11, 2021

BevCanna’s extensive distribution network includes more than 3,000 points of retail distribution through its market-leading TRACE brand, its Pure Therapy natural health and wellness e-commerce platform, its fully licensed Canadian cannabis manufacturing and distribution network, and a partnership with #1 U.S.

Research and Development 81

Research and Development Retail Events Media 81

Cannabis Law Report

OCTOBER 19, 2021

Unlike other therapies, MYMD-1 has been shown to selectively block TNF-? In addition, the drug is not immunosuppressive and has not been shown to cause the serious side effects common with traditional therapies that treat inflammation. a driver of chronic inflammation. No approved TNF inhibitor has ever been dosed orally.

Pharmaceutical 40

Pharmaceutical Therapy Clinical Trials Chronic Pain 40

Cannabis Law Report

OCTOBER 13, 2021

Most notably, drug-assisted therapy often improves the patient-therapist relationship and increases flexibility in the patient’s mind, allowing patients to discover and incorporate new ways of addressing their conditions. There is no certainty that any of these events will occur. The PPA, which was filed on Friday, Oct.

Medicine 52

Medicine Research and Development Therapy Events 52